Vistagen Therapeutics, Inc.
VTGNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeVistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The $8.0M market capitalization puts VTGN squarely in micro-cap range for its industry. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Market Cap
$8.0M
Beta
0.33
P/E (TTM)
—
P/E (Fwd)
-0.12
EPS (TTM)
$-1.66
EPS (Fwd)
$-1.54
ROE
-166.5%
ROA
-83.2%
Cash
$31.7M
Total Debt
$783,000
Free CF
-$37.0M
52W Change
-95.6%
Annual Financials
Cash vs Debt
Where VTGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, VTGN finished 52.38% below its 150-day moving average ($0.42) and 57.45% below its 200-day moving average ($0.47). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VTGN overbought or oversold?
At the October 20, 2026 close, VTGN's RSI(14) was 8.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $31.7M in cash comfortably exceeding the $783K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$37.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -166.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from -$227K (2023) to $1.3M (2026), reflecting a 659% increase over the period.
With a beta below 0.7, Vistagen Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, VTGN has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Vistagen Therapeutics, Inc.'s trajectory.